Nexus Pharmaceuticals LLC v. Exela Pharma Sciences, LLC

PGR2024-00016

Nexus Pharmaceuticals has filed a PGR petition challenging all 30 claims of Exela Pharma Sciences' L‑cysteine parenteral nutrition patent, asserting lack of enablement, insufficient written description, and, alternatively, obviousness over the Sandoz label.

Jurisdiction
US PTAB
Case Number
PGR2024-00016
Filing Date
2 August 2024
Status
ok

Related Cases

patentIPR2024-01030

Luxottica of America Inc., et al.vsE-Vision Optics, LLC

Luxottica successfully petitioned to institute IPR against E-Vision Optics regarding eyewear technology, overcoming initial procedural hurdles. The Board found that Petitioner adequately established a reasonable likelihood of proving anticipation for key claims based on prior art references.

patentIPR2024-01212

Avanos Medical, Inc.vsStratus Medical, LLC

The PTAB found all 29 challenged claims unpatentable by a preponderance of evidence. The Board rejected the Patent Owner's argument that the invention was limited to RF neurotomy, adopting Petitioner's broader view of 'thermal ablation systems.'

patentIPR2024-00986

Ericsson Inc. et al.vsActive Wireless Technologies LLC

Ericsson and Nokia, together with patent owner Active Wireless Technologies, filed a joint motion to have their settlement agreements kept confidential under statutory provisions, seeking to separate the materials from the public PTAB file.

patentIPR2025-01143

ProAmpac Holdings Inc.vsSigma Technologies Int'l, LLC et al.

ProAmpac has filed an IPR petition seeking cancellation of all 15 claims of U.S. Patent 11,072,148, asserting anticipation and obviousness over four prior‑art references.

patentIPR2025-00482

Samsung Electronics Co., Ltd. et al.vsHEADWATER RESEARCH LLC

Samsung has filed an IPR petition seeking to invalidate Headwater Research’s patent on security techniques for device‑assisted services, asserting obviousness over multiple prior‑art references. The petition argues that the Board should institute the review and that discretionary denial is unwarranted.

Arctic Invent — IP Strategy

Dealing with a patent challenge?

Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.

Talk to our patent team →

Disclaimer: This page contains an automated summary based on publicly available judicial records. The content is generated for informational purposes only and does not constitute legal advice. Always verify details against the original source judgment before relying on this information for any legal purpose. If you believe any information is inaccurate, please contact us.

Strategy Consult

Facing a similar patent matter?

Arctic's litigation team uses precedent data like this to build winning arguments.

Get a Strategy Call